The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | DREAMM-6: belamaf-based combination therapy in R/R MM
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, outlines the findings of the Phase I/II DREAMM-6 study (NCT03544281) of a belantamab mafodotin (belamaf)-based combination therapy in relapsed/refractory multiple myeloma patients. Belamaf is an anti-BCMA antibody-drug conjugate, shown to induce deep and durable responses in heavily pretreated myeloma patients as a monotherapy. A preclinical suggestion of synergy with standard of care agents led to the examination of combined belamaf, bortezomib and dexamethasone treatment in Arm B of this study. The trial is ongoing, with promising interim efficacy and safety data endorsing enrollment of a Phase III study of the triplet in comparison to daratumumab, bortezomib and dexamethasone (DREAMM-7). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
